11. Myasthenia gravis Clinical trials / Disease details
Clinical trials : 315 / Drugs : 232 - (DrugBank : 77) / Drug target genes : 46 - Drug target pathways : 126
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05067348 (ClinicalTrials.gov) | November 30, 2021 | 23/9/2021 | Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis | A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis | Myasthenia Gravis, Generalized | Drug: Tocilizumab Injectable Product | Tang-Du Hospital | NULL | Not yet recruiting | 18 Years | 80 Years | All | 64 | Phase 2 | China |